REX pitches the fund as covering developers, manufacturers and delivery platforms rather than just GLP-1 makers. It isn't open for purchase yet.
Recap by typeshit. Post by REX Shares on X.
The surgeon says that after a 45 lb loss on a GLP-1, getting enough daily protein with a low appetite becomes the harder part.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
The writer cites a Gallup survey putting about 11 percent of Americans on GLP-1s and argues the real share is likely higher, and wants use discussed openly.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
Eligible beneficiaries can get some GLP-1 drugs cheaper, but BMI and medical conditions decide who qualifies, and it runs apart from Part D.
Orexo says its first preclinical in vivo study of an oral semaglutide built on AmorphOX showed promising bioavailability. Animal data only so far.
Loading…